UNVO Stock Overview
Univo Pharmaceuticals Ltd engages in the development, production, and supply of medical cannabis products. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 2/6 |
| Dividends | 0/6 |
My Notes
Capture your thoughts, links and company narrative
Univo Pharmaceuticals Ltd Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ₪0.093 |
| 52 Week High | ₪1.76 |
| 52 Week Low | ₪0.09 |
| Beta | 0.78 |
| 1 Month Change | 0% |
| 3 Month Change | -7.00% |
| 1 Year Change | -94.34% |
| 3 Year Change | -94.56% |
| 5 Year Change | n/a |
| Change since IPO | -97.99% |
Recent News & Updates
Shareholder Returns
| UNVO | IL Biotechs | IL Market | |
|---|---|---|---|
| 7D | 0% | 5.4% | -0.3% |
| 1Y | -94.3% | -23.2% | 25.3% |
Return vs Industry: UNVO underperformed the IL Biotechs industry which returned 18.8% over the past year.
Return vs Market: UNVO underperformed the IL Market which returned -8.8% over the past year.
Price Volatility
| UNVO volatility | |
|---|---|
| UNVO Average Weekly Movement | n/a |
| Biotechs Industry Average Movement | 6.3% |
| Market Average Movement | 4.3% |
| 10% most volatile stocks in IL Market | 8.4% |
| 10% least volatile stocks in IL Market | 3.0% |
Stable Share Price: UNVO's share price has been volatile over the past 3 months.
Volatility Over Time: Insufficient data to determine UNVO's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1993 | 76 | Golan Bitton | www.unv-medicine.com |
Univo Pharmaceuticals Ltd engages in the development, production, and supply of medical cannabis products. The company was formerly known as Di-Pharm Ltd and changed its name to Univo Pharmaceuticals Ltd in September 2018. Univo Pharmaceuticals Ltd was incorporated in 1993 and is based in Ashkelon, Israel.
Univo Pharmaceuticals Ltd Fundamentals Summary
| UNVO fundamental statistics | |
|---|---|
| Market cap | ₪2.84m |
| Earnings (TTM) | -₪32.19m |
| Revenue (TTM) | ₪43.89m |
0.1x
P/S Ratio-0.1x
P/E RatioIs UNVO overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| UNVO income statement (TTM) | |
|---|---|
| Revenue | ₪43.89m |
| Cost of Revenue | ₪43.25m |
| Gross Profit | ₪639.00k |
| Other Expenses | ₪32.83m |
| Earnings | -₪32.19m |
Last Reported Earnings
Jun 30, 2022
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.05 |
| Gross Margin | 1.46% |
| Net Profit Margin | -73.35% |
| Debt/Equity Ratio | 193.1% |
How did UNVO perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2023/03/14 04:21 |
| End of Day Share Price | 2022/12/15 00:00 |
| Earnings | 2022/06/30 |
| Annual Earnings | 2021/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Univo Pharmaceuticals Ltd is covered by 0 analysts. of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|